Efficacy of Recombinant Gamma Interferon for Treatment of Systemic Cryptococcosis in SCID Mice

Karl V. Clemons, Jon E. Lutz and David A. Stevens


Updated information and services can be found at:
http://aac.asm.org/content/45/3/686

**REFERENCES**

This article cites 21 articles, 16 of which can be accessed free at:
http://aac.asm.org/content/45/3/686#ref-list-1

**CONTENT ALERTS**

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article),

more»

Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml
To subscribe to another ASM Journal go to: http://journals.asm.org/site/subscriptions/
Efficacy of Recombinant Gamma Interferon for Treatment of Systemic Cryptococcosis in SCID Mice

KARL V. CLEMONS,* JON E. LUTZ, AND DAVID A. STEVENS

Department of Medicine, Division of Infectious Diseases, and California Institute for Medical Research, San Jose, California 95128, and Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California 94305

Received 6 January 2000/Returned for modification 16 July 2000/Accepted 25 October 2000

We have previously shown that gamma interferon (IFN-γ) is a useful adjunct to therapy of experimental systemic cryptococcosis in normal mice. To better emulate AIDS patients, SCID mice were infected intravenously with Cryptococcus neoformans. Mice received no therapy, 3 mg of amphotericin B (AmB) per kg of body weight, or 10^6 U of IFN-γ alone (prophylactically and therapeutically or only therapeutically) or with AmB. In the first experiment, >75% of the mice survived. Therapy with AmB alone was efficacious compared to no therapy in all organs. Both regimens of IFN-γ alone were efficacious in the brain and lungs, and the combination of AmB and IFN-γ showed significant synergy in the kidneys. AmB alone cured 40% of mice of infection, whereas the combination regimens cured >50% of the mice and 90% of the brain infections. In a second study, IFN-γ again proved efficacious alone, and when given with AmB its efficacy was improved. Therapeutic IFN-γ alone was effective only in the liver compared to no therapy, and the combination regimen, although highly effective, showed no significant synergy. In a third experiment, AmB alone or in combination with IFN-γ prolonged survival compared to no therapy or IFN-γ alone. The combination regimen showed significant synergy over AmB alone in the brain, liver, kidneys, and lungs. AmB alone cured no mice of infections in more than two organs, whereas AmB in combination with IFN-γ cured 55% of infections in three or more organs. These results indicate that IFN-γ has therapeutic efficacy in severely immunodeficient animals, especially in combination with AmB. Significant synergistic activity was noted in all organs except the spleen. Overall, IFN-γ has utility as an adjunctive therapy against systemic cryptococcosis in the severely immunocompromised host.

Cryptococcal meningitis is a fungal disease that requires therapeutic intervention, whether it is manifested in immunocompetent or immunocompromised patients (18). Although currently available antifungal therapies have been shown to be beneficial, relapses while on therapy and mortality are not uncommon (8, 9, 12). Thus, the improvement of therapeutic options is of prime importance in the successful treatment of this disease. One potential therapeutic option involves the use of cytokines as an adjunct to conventional antifungal therapy (18, 23).

Previous studies have demonstrated that adjunctive cytokine therapy with interleukin-12 or gamma interferon (IFN-γ) could improve the outcome of experimental murine cryptococcosis (5, 7, 15, 17, 23). In addition, synergistic efficacy has been demonstrated by the addition of either interleukin-12, an inducer of IFN-γ, or IFN-γ to a regimen of conventional therapy (5, 15, 17). However, these studies were done with nonimmunocompromised animals, whereas the majority of patients with meningeal cryptococcosis are immunocompromised.

In the present study, we have examined the utility of IFN-γ alone or in combination with amphotericin B (AmB) therapy against systemic cryptococcosis established in a severely immunocompromised host, namely, the SCID mouse. This animal has severe combined immunodeficiency with no functional B or T cells and most closely emulates the patient with AIDS (4). Our rationale for choosing this model was to determine whether immunomodulation with IFN-γ alone or as an adjunct to conventional AmB treatment would have therapeutic efficacy in a host incapable of a normal cell-mediated or humoral immune response. Were IFN-γ to prove beneficial in this system, it might provide a clinical option for the treatment of cryptococcal meningitis in immunocompromised patient populations. (These studies were presented in part to the 4th Congress of the European Confederation of Medical Mycology held in Glasgow, Scotland, in May 1998.)

MATERIALS AND METHODS

Mice. The animals used in this experiment were 6-week-old male C.B-17 scid/scid (SCID) mice. These mice were purchased from Taconic, Germantown, N.Y. Mice were housed in sterile microisolator cages and were provided sterilized chow and sterilized water ad libitum. Strict protocols were followed in handling these mice to reduce the possibility of animals contracting opportunistic infections. Mice were housed five per cage. All cages were changed at least twice weekly.

Experiment 1. Six groups of 10 mice each were randomly assigned to therapy groups. The groups were mice receiving no therapy, mice receiving 100,000 U of IFN-γ (recombinant murine IFN-γ supplied by Genentech, Inc., South San Francisco, Calif.) given intravenously (i.v.) in 0.25 ml either therapeutically or prior to infection and then therapeutically, and mice receiving 3.0 mg of AmB (Pharma-Tek, Inc., Huntington, N.Y.) per kg of body weight given intraperitoneally in 0.20 ml alone or in combination with one of the two IFN-γ regimens. IFN-γ was administered i.v. on the basis of prior data in our laboratory, which indicated better efficacy by this route than by a subcutaneous route in normal animals (data not shown).

Experiments 2 and 3. Four groups of 10 mice each were randomly assigned to therapy groups. Mice received either no therapy, 100,000 U of IFN-γ (Genen-
TABLE 1. Recovery of *C. neoformans* from organs of surviving SCID mice treated with IFN-γ or AmB alone or in combination in experiment 1

<table>
<thead>
<tr>
<th>Treatment</th>
<th>No. of mice alive/no. cured (no. total)</th>
<th>Log_{10} geometric mean CFU of <em>C. neoformans</em> per organ (no. of organs free of infection) (95% confidence interval) recovered from:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Brain</td>
</tr>
<tr>
<td>None</td>
<td>7/0 (9)</td>
<td>3.02 (1) (1.5–4.6)</td>
</tr>
<tr>
<td>Therapeutic IFN-γ alone</td>
<td>10/0 (10)</td>
<td>1.69 (4) (0.5–2.9)</td>
</tr>
<tr>
<td>Prophylactic and therapeutic IFN-γ alone</td>
<td>10/0 (10)</td>
<td>0.84 (5) (0–1.7)</td>
</tr>
<tr>
<td>AmB alone</td>
<td>10/4 (10)</td>
<td>0.73 (8) (0–2.2)</td>
</tr>
<tr>
<td>Therapeutic IFN-γ plus AmB</td>
<td>10/5 (10)</td>
<td>0.79 (8) (0–2.0)</td>
</tr>
<tr>
<td>Prophylactic and therapeutic IFN-γ plus AmB</td>
<td>9/6 (9)</td>
<td>0 (9)^a</td>
</tr>
</tbody>
</table>

^a P < 0.05 to 0.001 versus controls dependent on comparison.  
^b P < 0.05 versus AmB alone.

RESULTS

Experiment 1. Over the course of the 29 days of experimental infection, 7 of 9 untreated control mice survived. The two deaths occurred on days 21 and 29 postinfection. A single mouse succumbed to infection on day 25 postinfection in the group receiving pretreatment and therapeutic IFN-γ alone. No other mice died of infection with any other regimen. Because of the low mortality in the untreated control group, no survival advantage could be demonstrated for any treatment regimen.

The primary parameter used to evaluate the efficacy of IFN-γ therapy in this study was the comparative burden of *C. neoformans* recovered from the organs at day 29 postinfection. The log_{10} geometric mean burdens and the 95% confidence intervals of these burdens are presented in Table 1. In the brain, kidneys, and lungs, the untreated controls had the highest mean burdens of *C. neoformans*, whereas in the livers and spleens, mice given IFN-γ alone on a pretreatment and therapeutic schedule had higher mean burdens than did the untreated controls. Thus, all treatment regimens showed some efficacy in reducing the mean burden of yeast cells in three or more organs.

The significance of the apparent treatment efficacies was determined by comparison of the burdens between treatment groups. Therapy with AmB alone was efficacious compared to no treatment in all five organs in reducing the burden of organisms. Therapy with IFN-γ alone by either dosing schedule also proved effective. However, this activity was significant only in the brain and lungs for both regimens and in the liver for the...
therapeutic regimen of IFN-γ. The addition of IFN-γ to the AmB regimen further increased the efficacy of the treatment in all organs. However, statistically significant synergistic activity was noted only in the kidneys.

With respect to cure (defined as no detectable infection in the organs assayed), only mice given a regimen which included AmB were free of detectable C. neoformans in all five organs. AmB alone cleared the infection in 40% of the treated animals, whereas AmB plus therapeutic IFN-γ cleared it in 50% of the mice. Administration of IFN-γ as a pretreatment and then therapeutically in combination with AmB cleared 66% of the treated mice of infection. All were free of infection in the brain and kidney.

**Experiment 2.** Over the course of the 28 days of experimental infection, 6 of 10 untreated control mice survived. The deaths occurred on days 15, 17, 24, and 26 postinfection. No other mice died of infection with any other regimen. Because of the low mortality in the untreated control group, no survival advantage could be demonstrated for any treatment regimen. The mean burdens of C. neoformans were highest in the untreated control group and the IFN-γ-treated group (Table 2). In all organs, except the liver, those animals given IFN-γ carried higher, but not significant, mean burdens than did surviving mice that had received no treatment. AmB treatment alone was efficacious in all five organs in reducing the burden of organisms. Therapy with IFN-γ alone proved significantly effective only in the liver. The combination regimen of IFN-γ and AmB was more efficacious than AmB alone in organs other than the brain, but this did not attain statistical significance.

Similar to the results of the first experiment, AmB alone cleared infection in 20% of the treated animals, whereas AmB plus IFN-γ cleared the infection in 60% of the mice. However, by Fisher’s exact test this comparative rate of cure was not significantly different (P = 0.085).

**Experiment 3.** Over the course of the 30-day experimental infection, 2 of 10 untreated control mice survived. In comparison, 6 of 10 mice given AmB alone, 0 of 10 mice given IFN-γ alone, and 9 of 9 mice given the combination regimen of AmB and IFN-γ survived (1 mouse died of an injection-related trauma and was not included in any analysis) (Fig. 1). Statistical comparison showed that both AmB and the combination regimen significantly prolonged survival in comparison with no treatment or IFN-γ alone (P < 0.01 to 0.001). IFN-γ alone did not significantly prolong survival, nor was synergy demonstrated with the combination regimen, i.e., IFN-γ plus AmB was equivalent to AmB alone, and IFN-γ alone was equivalent to no treatment (P < 0.05).

The comparative burdens of C. neoformans recovered from the organs at 30 days postinfection are presented in Table 3. AmB treatment alone was efficacious in only the spleen and liver in reducing the burden of organisms. The addition of IFN-γ to the AmB regimen increased the efficacy of the treatment in all organs except the spleen (Table 3). Statistically significant synergistic activity was noted in the brain, liver, kidneys, and lungs with the AmB and IFN-γ regimen.

AmB alone cleared none of the treated animals in more than two organs, whereas AmB plus IFN-γ cleared 55% of the mice of detectable infection in three or more organs; one mouse was free of infection in all five organs.

**DISCUSSION**

There exists a substantial body of literature dealing with the involvement of IFN-γ in host resistance to C. neoformans (1–5, 7, 10, 11, 15, 16, 19–22, 24). Both in vitro and in vivo studies have shown IFN-γ to play a role in host resistance to this organism. In our previous studies, we have shown that in immunocompetent mice the administration of IFN-γ in combination with AmB, but not fluconazole, significantly improves the host’s capacity to restrict the proliferation of the organism, especially in the brain, in a synergistic manner (17).

The question of whether IFN-γ would have utility in the treatment of systemic cryptococcosis in a severely immunocompromised host has been addressed in the present studies.

---

**TABLE 3. Recovery of C. neoformans from organs of surviving SCID mice treated with IFN-γ or AmB alone or in combination in experiment 3**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>No. of mice alive/no. cured (no. alive)</th>
<th>Log$_{10}$ geometric mean CFU of C. neoformans per organ (no. of organs free of infection (95% confidence interval) recovered from:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Brain</td>
</tr>
<tr>
<td>None</td>
<td>2/0 (10)</td>
<td>0 (2)</td>
</tr>
<tr>
<td>IFN-γ alone</td>
<td>0/0 (10)</td>
<td></td>
</tr>
<tr>
<td>AmB</td>
<td>6/0 (10)</td>
<td>5.79 (0) (3.7–7.9)</td>
</tr>
<tr>
<td>IFN-γ plus AmB</td>
<td>9/1 (9)</td>
<td>3.82 (3)$^a$ (1.6–6.1)</td>
</tr>
</tbody>
</table>

$^a$ P < 0.05 to 0.001 versus controls dependent on comparison.

$^b$ P < 0.05 to 0.01 versus AmB alone dependent on comparison.
We have demonstrated that IFN-γ indeed shows therapeutic efficacy in severely immunodeficient animals. Although the results from the three experiments are not in exact accord with one another, all are indicative of IFN-γ having therapeutic efficacy against systemic cryptococcosis, particularly against meningeval infection. In each experiment, mice given the combination regimen of IFN-γ and AmB carried lower mean burdens of yeast cells in the brain, which is the main target organ in this model, than did untreated controls. Thus, the efficacy of IFN-γ was demonstrated when given alone as well as in combination with conventional AmB therapy. In some instances, the efficacy of sole IFN-γ treatment was not different from that of conventional AmB treatment.

It is important to note that the combination regimens effected complete cures in the greatest number of animals (experiments 1 and 2) and in the greatest number of organs (experiments 1 to 3). However, it should be noted that the cure rates observed in these studies were very likely influenced by the severity of the infections. In the two studies in which few or no cured animals were observed in these studies were very likely influenced by the severity of the infections. In the two studies in which few or no cured animals were observed, this was demonstrated when given alone as well as in combination with conventional AmB therapy. In some instances, the efficacy of sole IFN-γ treatment was not different from that of conventional AmB treatment.

ACKNOWLEDGMENT

These studies were funded in part by a grant from Genentech, Inc.

REFERENCES


20. Salkowski, C. A., and E. Balish. 1995. Interleukin-12 (IL-12) and IL-18 synergistically induce the fun


26. Zhang, T., K. Kawakami, M. H. Qureshi, H. Okamura, M. Kurimoto, and A. Saijo. 1997. Interleukin-12 (IL-12) and IL-18 synergistically induce the fun

Downloaded from http://aac.asm.org/ on March 5, 2014 by PENN STATE UNIV